Published • loading... • Updated
FTC: Amgen patent arguments a “mockery of Section 2”
Summary by globalcompetitionreview.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FTC: Amgen patent arguments a “mockery of Section 2”
Acquisitions of patent applications should not receive blanket antitrust protections under the First Amendment, the Federal Trade Commission has argued as Amgen seeks to fend off allegations that it cornered the market for its blockbuster Enbrel arthritis drug.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
